Novavax Prices Public Offering of Common Stock
11 Abril 2018 - 09:50PM
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company
committed to delivering novel products to prevent infectious
diseases, today announced that it has priced an underwritten public
offering of 30,303,050 shares of common stock at a price to the
public of $1.65 per share for gross proceeds of $50 million, before
deducting the underwriting discounts and offering expenses. In
connection with this offering, Novavax has granted the underwriters
a 30-day option to purchase up to an additional 4,545,457 shares of
its common stock. If the underwriters exercise this option in full,
Novavax will have sold 34,848,507 shares of its common stock.
Novavax intends to use the net proceeds from
this offering for general corporate purposes, including but not
limited to working capital, capital expenditures, research and
development expenditures related to its clinical and preclinical
vaccine candidates, clinical trial expenditures, as well as
acquisitions and other strategic purposes. The offering is expected
to close on or about April 16, 2018, subject to the satisfaction of
customary closing conditions.
Citigroup and Piper Jaffray & Co. are acting as joint
book-running managers for the offering. Cantor Fitzgerald & Co.
is also acting as a book-running manager. Ladenburg Thalmann and B.
Riley FBR are acting as co-managers.
A preliminary prospectus supplement and the
prospectus relating to the proposed offering have been filed with
the Securities and Exchange Commission (SEC). The offering may be
offered only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy, nor will there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction. When available, copies of the final prospectus
supplement and the prospectus relating to the proposed offering can
be obtained at the SEC’s website http://www.sec.gov or from
Citigroup and Piper Jaffray & Co., Attention: Citigroup, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at (800) 831-9146; or Piper
Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, by
telephone at (800) 747-3924 or by email at prospectus @pjc.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biotechnology company committed to delivering novel products to
prevent infectious diseases. Its RSV and influenza nanoparticle
vaccine candidates are Novavax’ most advanced clinical programs and
are at the forefront of the Novavax’ efforts to improve global
health.
Forward-Looking Statements
Statements contained in this press release,
including those relating to the expected closing of the offering,
and those statements using words such as “expects” and “intends”
are forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and
uncertainties include, but are not limited to: our ability to
successfully complete the offering on terms and conditions
satisfactory to us; the possible adverse impact on the market price
of our shares of common stock due to the dilutive effect of the
securities to be sold in the offering; our planned use of the
proceeds from this offering; capital market risks; our ability to
raise additional capital when needed; and other risk factors
identified in Part I, Item 1A “Risk Factors,” of the Novavax Annual
Report on Form 10-K for the year ended December 31, 2017 as filed
with the Securities and Exchange Commission (SEC) and in other
reports filed from time to time with the SEC, including our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K,
which are all available at www.sec.gov. We caution investors not to
place considerable reliance on the forward-looking statements
contained in this press release. The forward-looking statements in
this press release speak only as of the date of this document, and
we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
Contact:
Investors:Erika TrahanSenior Manager, Investor & Public
Relationsir@novavax.com240-268-2000
Westwicke PartnersJohn
WoolfordJohn.woolford@westwicke.com443-213-0506
Media:Sam BrownMike Beyermikebeyer@sambrown.com312-961-2502
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Novavax (NASDAQ:NVAX)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024